These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8462177)

  • 1. Heterogeneity of high density lipoprotein particles.
    Fruchart JC; Ailhaud G; Bard JM
    Circulation; 1993 Apr; 87(4 Suppl):III22-7. PubMed ID: 8462177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients.
    Branchi A; Rovellini A; Sommariva D
    Int J Clin Pharmacol Res; 1995; 15(4):153-8. PubMed ID: 8871265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Receptors and molecular heterogeneity of lipoprotein particles containing apolipoprotein A-I].
    Broutin H; Puchois P; Ailhaud G; Barbaras R; Torpier G; Fruchart JC
    Ann Biol Clin (Paris); 1988; 46(1):16-23. PubMed ID: 2839056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of lipoprotein disorders.
    Breslow JL
    Circulation; 1993 Apr; 87(4 Suppl):III16-21. PubMed ID: 8462176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
    Staels B; Van Tol A; Fruchart JC; Auwerx J
    Isr J Med Sci; 1996 Jun; 32(6):490-8. PubMed ID: 8682657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension.
    Gazzaruso C; Buscaglia P; Garzaniti A; Bonetti G; Savino S; Mariotti S; Jucci A; Finardi G; Geroldi D
    J Cardiovasc Risk; 1996 Apr; 3(2):191-7. PubMed ID: 8836862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M; Sertić J; Duraković Z
    Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipoprotein particles LpA-I, LpA-I: A-II and LpB in coronary artery disease].
    Calvo C; Olmos A; Ulloa N; Bustos A; Toledo L; Durán D; Naveas R
    Rev Med Chil; 2000 Jan; 128(1):9-16. PubMed ID: 10883517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction.
    Gaeta G; Cuomo S; Capozzi G; Foglia MC; Barra S; Madrid A; Stornaiuolo V; Trevisan M
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):492-6. PubMed ID: 17962002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet and waist-to-hip ratio: important predictors of lipoprotein levels in sedentary and active young men with no evidence of cardiovascular disease.
    Mansfield E; McPherson R; Koski KG
    J Am Diet Assoc; 1999 Nov; 99(11):1373-9. PubMed ID: 10570674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What do we know about lipoproteins containing apo A-I?].
    Barkia A
    Ann Biol Clin (Paris); 1990; 48(8):529-35. PubMed ID: 2288439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
    Hsu HC; Lee YT; Yeh HT; Chen MF
    J Lab Clin Med; 2001 Jun; 137(6):414-21. PubMed ID: 11385362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.
    Boffa MB; Marcovina SM; Koschinsky ML
    Clin Biochem; 2004 May; 37(5):333-43. PubMed ID: 15087247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein Lp(a) excess and coronary heart disease.
    Stein JH; Rosenson RS
    Arch Intern Med; 1997 Jun; 157(11):1170-6. PubMed ID: 9183227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate.
    Brinton EA
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):431-40. PubMed ID: 8630670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lp(a) and the risk of coronary heart disease.
    Bihari-Varga M; Kostner G; Czinner A
    Eur J Epidemiol; 1992 May; 8 Suppl 1():33-5. PubMed ID: 1387093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL heterogeneity and atherosclerosis.
    Tailleux A; Fruchart JC
    Crit Rev Clin Lab Sci; 1996; 33(3):163-201. PubMed ID: 8828000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.